<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00870350</url>
  </required_header>
  <id_info>
    <org_study_id>2008-008195-13</org_study_id>
    <nct_id>NCT00870350</nct_id>
  </id_info>
  <brief_title>An Immunogenicity and Safety Study of Tetanus, Diphtheria and Acellular Pertussis Vaccine Booster</brief_title>
  <acronym>Tdap Booster</acronym>
  <official_title>An Immunogenicity and Safety Study of Combined Adsorbed Tetanus, Low Dose Diphtheria and Acellular Pertussis Vaccine (Td5ap and Td1aP) Given as a School-leaving Booster to 14-15-year-old Children Primed With a Five Component Acellular Pertussis Vaccine at 3, 5 and 12 Months of Age, and a Booster Dose at 5½ Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swedish Institute for Infectious Disease Control</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MCM Vaccines B.V.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Statens Serum Institut</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Swedish Institute for Infectious Disease Control</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label, randomized, multi-centre study in which 400 subjects, divided into two groups,&#xD;
      will receive Td5ap or Td1aP as a single injection. We will then describe the immune response&#xD;
      and safety profile of the combined vaccine booster.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The vaccines in the study are COVAXIS (Td5ap), Sanofi Pasteur Canada, and diTekiBooster&#xD;
      (Td1aP), Statens Serum Institut, Denmark.&#xD;
&#xD;
      The primary objective of the study is to describe the immune response to diphtheria toxin,&#xD;
      tetanus toxoid, pertussis toxin, filamentous haemagglutinin (FHA), fimbriae 2/3 and pertactin&#xD;
      four weeks after immunization with Td1aP and Td5ap.&#xD;
&#xD;
      The secondary objectives include:&#xD;
&#xD;
        -  describing the safety of a fith dose of DTP vaccines in 14-15 year-old children by&#xD;
           observing systemic and local adverse reactions&#xD;
&#xD;
        -  describing pre-booster antibody levels&#xD;
&#xD;
        -  describing pre-booster and post-booster IgG and IgA levels in saliva&#xD;
&#xD;
        -  describing in a subpopulation the pre-booster and post-booster T cell immune responses&#xD;
           as determined by the production of cytokines&#xD;
&#xD;
        -  describing in a subpopulation the pre-booster and post-booster B cell immune responses&#xD;
           as determined by the number of effector and memory B-cells&#xD;
&#xD;
      The sample size is 400 subjects (200 in group 1 and 200 in group 2). It will be an&#xD;
      open-label, randomized, multi-centre study in which group 1 will receive Td5ap as a single&#xD;
      injection and group 2 will receive Td1aP as a single injection. DTP antibodies will be&#xD;
      measured before and 28 days (+ 14 days) after Td5ap and Td1aP vaccination. The proportion of&#xD;
      children with positive IgG antibody response will be measured in each study arm. Sera will be&#xD;
      tested blindly by established ELISA methods and saliva samples will be analyzed by&#xD;
      exploratory assays. In a subpopulation cellmediated immunity will be analyzed. The safety&#xD;
      evaluation criteria will be the percentage of subjects with adverse events describing&#xD;
      injection-site adverse reactions, systemic adverse events, daily temperatures and serious&#xD;
      adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2009</start_date>
  <completion_date type="Anticipated">June 2010</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to describe in each arm the immune response to diptheria toxin, tetanus toxoid, pertussis toxin, FHA, fimbriae 2/3 and pertactin four weeks after immunization with Td1aP and Td5ap</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety of a fith dose of DTP vaccines</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pre-booster antibody levels</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pre-booster and post-booster IgG and IgA levels</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pre-booster and post-booster T cell immune responses</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pre-booster and post-booster B cell immune responses</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Tetanus</condition>
  <condition>Diphtheria</condition>
  <condition>Pertussis</condition>
  <arm_group>
    <arm_group_label>Td5ap</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 1 receiving Td5ap as a single intramuscular injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Td1aP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 2 receiving Td1aP as a single intramuscular injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Td5ap</intervention_name>
    <description>Intramuscular injection of 0.5 mL Td5ap (COVAXiS) on day 1.</description>
    <arm_group_label>Td5ap</arm_group_label>
    <other_name>COVAXiS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Td1aP</intervention_name>
    <description>Intramuscular injection of 0.5 mL Td1aP (diTekiBooster) on day 1.</description>
    <arm_group_label>Td1aP</arm_group_label>
    <other_name>diTekiBooster</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy subject&#xD;
&#xD;
          -  14-15 years old&#xD;
&#xD;
          -  eligible for their school-leaving booster for DTP&#xD;
&#xD;
          -  received a complete primary vaccination with a 5-component acellular pertussis vaccine&#xD;
             (DT5aP-IPV-Hib) at 3, 5 and 12 months of age and vaccinated with a 5-component&#xD;
             acellular pertussis vaccine (Td5aP-IPV or Td5aP + IPV) as a booster at 5½ years of age&#xD;
&#xD;
          -  informed consent form signed by the subject and parent(s)/legal representative&#xD;
&#xD;
          -  subject understand and comply with the study procedures (i.e. able to read and write&#xD;
             Swedish)&#xD;
&#xD;
          -  female must provide an agreement that they are either sexually continent or practice&#xD;
             adequate contraceptive methods (intra-uterine contraceptive device (IUCD), hormonal&#xD;
             contraceptives, condoms or other adequate barrier contraception).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  acute febrile illness or axillary temperature ≥38.0°C at the time of vaccination&#xD;
&#xD;
          -  receipt of immunoglobulin within the previous 3 months, immunosuppression (e g&#xD;
             evidence of impaired cell mediated immunity, receipt of immunosuppressant drugs within&#xD;
             the previous 3 months or receipt of systemic corticosteroids given daily or on&#xD;
             alternate days at ≥20 mg/day prednisone equivalent during &gt;14 days within the past 30&#xD;
             days)&#xD;
&#xD;
          -  receipt of a non-study vaccine in the past 30 days&#xD;
&#xD;
          -  evolving encephalopathy not attributable to another identifiable cause within 7 days&#xD;
             of administration of a previous dose of any vaccine&#xD;
&#xD;
          -  booster vaccination with tetanus, low dose diphtheria and acellular pertussis vaccine&#xD;
             since the booster vaccination at 5½ years of age&#xD;
&#xD;
          -  previous clinical or bacteriological diagnosis of diphtheria, tetanus or pertussis&#xD;
&#xD;
          -  hypersensitivity to any component of any of the study vaccines&#xD;
&#xD;
          -  current participation in any other clinical trial or participation in any clinical&#xD;
             trial in the previous month&#xD;
&#xD;
          -  inability to adhere to the protocol, including plans to move from the area&#xD;
&#xD;
          -  severe chronic disease&#xD;
&#xD;
          -  family history of congenital or hereditary immunodeficiency&#xD;
&#xD;
          -  any sever thrombocytopenia or any other coagulation disorder that would contraindicate&#xD;
             intramuscular injection&#xD;
&#xD;
          -  any medical condition, which in the opinion of the investigator, might interfere with&#xD;
             the evaluation of the study objectives.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leif Gothefors, Prof. em.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swedish Institute for Infectious Disease Control</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eva Netterlid</last_name>
    <role>Study Director</role>
    <affiliation>Swedish Institute for Infectious Disease Control</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Swedish Institute for Infectious Disease Control</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <study_first_submitted>March 26, 2009</study_first_submitted>
  <study_first_submitted_qc>March 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2009</study_first_posted>
  <last_update_submitted>June 4, 2010</last_update_submitted>
  <last_update_submitted_qc>June 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. em. Leif Gothefors</name_title>
    <organization>Swedish Institute for Infectious Disease Control</organization>
  </responsible_party>
  <keyword>immunogenicity</keyword>
  <keyword>safety</keyword>
  <keyword>tetanus</keyword>
  <keyword>diphtheria</keyword>
  <keyword>acellular</keyword>
  <keyword>pertussis</keyword>
  <keyword>vaccine</keyword>
  <keyword>booster</keyword>
  <keyword>adverse event</keyword>
  <keyword>adverse reaction</keyword>
  <keyword>DT1aP</keyword>
  <keyword>DT5ap</keyword>
  <keyword>FHA</keyword>
  <keyword>fimbriae</keyword>
  <keyword>pertactin</keyword>
  <keyword>SMI</keyword>
  <keyword>Smittskyddsinstitutet</keyword>
  <keyword>Immune response and safety profile to a Tdap booster</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Tetany</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

